Chaperone Tecnologies, Inc. is developing antimicrobial products, based on a novel and proprietary mechanism of action, for difficult-to-treat and drug-resistant organisms across a broad range of infectious diseases.
Chaperone’s proven technology has already yielded the company’s first product, a potent antimicrobial which is in development for treating complicated drug resistant Urinary Tract Infections.

Our core technology platform can produce a sustainable pipeline of unique products for human and non-human applications, including:

• Antimicrobials, antifungals, and antiparasitics targeting multi-drug resistant organisms across a range of infectious diseases
• A family of biopesticides, feed additives, biopreservatives, antifungals, and insecticides
• A family of non-toxic antimicrobials and biocides for the meat, poultry and aquaculture processing industries

Novel Mechanism of Action

Chaperone’s research is centered around our discoveries of the proven activity of native, short, proline-rich peptides and their derivatives, and the use of our novel pyrrhocoricin and drosocin-based analogs, to block protein folding by inhibiting interaction with the molecular chaperone DnaK. DnaK is a unique, vital, intracellular structure that is responsible for correcting misshapen proteins, a necessary step in the life of any organism. When Chaperone’s compounds bind to intracellular DnaK, it is prevented from performing its critical role in the organism’s cellular lifecycle, therefore killing the target organism.

As the binding site of our proprietary peptides is distinct from homologous targets in mammals, this suggests that these peptides are non-toxic to humans---and offer a novel and potent mechanism of action to which infectious diseases have not developed resistance.

Lead Compound

Chaperone's lead compound, CHP-105, is being developed for the treatment of complicated urinary tract infections. It exhibits high potency vs. multi-drug resistant variants of major uropathogens in vitro under conditions where standard antibiotics remain inactive, and significantly reduces bacterial counts in animal UTI models.

Chaperone believes that an IND is possible within 12-18 months.

Chaperone will expand development of its proprietary target-specific technology into products for treating a broad array of susceptible organisms.

Based on their activity profile and unique mechanism, Chaperone’s compounds are expected to potentially exhibit efficacy across an even broader array of multi-drug resistant organisms and fungi, such as those responsible for Respiratory Tract Infections (especially those causing life-threatening lung infections in cystic fibrosis patients), gastrointestinal infections, and fungal/parasitic diseases.